Bioporto A/s · OMXCOP:BIOPOR

Bioporto A/s — FY2025 Earnings Presentation

11 slides from Bioporto A/s's earnings presentation, Feb 6, 2026

  1. Slide 1: 2025 Preliminary figures, Guidance 2026 and Business Update

    BioPorto 2025 Preliminary figures, Guidance 2026 and Business Update Carsten Buhl, CEO & Niels Høy Nielsen, CFO February 6, 2026 CONFIDENTIAL | © Copyright BioPorto | 1

  2. Slide 2: Forward-looking statements

    Forward-looking statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte

  3. Slide 3: Invest in AKI Diagnostic - Invest in BioPorto

    Invest in AKI Diagnostic - Invest in BioPorto Early detection of AKI (Acute Kidney Injury) represents a major unmet need1 BioPorto’s ProNephro AKI (NGAL) is the first FDA-cleared test for pediatric AKI assessment Defined pathway for FDA approval and commercial launch of ProNephro AKI (NGAL) for adul

  4. Slide 4: Highlights for the fourth quarter of 2025

    Highlights for the fourth quarter of 2025 A commercial milestone in the fourth quarter of 2025 was the availability of ProNephroTM AKI (NGAL) for the US market. The “Forward” Strategic Plan was established in November. This is a three-year plan focusing on building market adoption, capturing high gr

  5. Slide 5: The "Forward" Strategic Plan

    The ”Forward” Strategic Plan Focus on Execution of Market Access & Commercialization to transform kidney care Aspirations 1 Adaption +60 US Hospitals 2H 2027 Cash + Validation Study flow Positive 2026 High +100 Global Hospitals FY 2028 Revenue 2 Growth + Adult Indication 2027 150-200m DKK +170 Globa

  6. Slide 6: +60 Hospitals by end of 2026 – Creating Adoption

    +60 Hospitals by end of 2026 – Creating Adoption Expected Development of # of US Hospitals from 2024-2026 +36% +60 • Creating awareness and understanding; to create the future demand 22% 44 • NGAL Research Use Only (RUO) & continued focus on 36 the Pediatric segment • Focus on the market in North Am

  7. Slide 7: Clinical validation study for adults – Creating Access

    Clinical validation study for adults – Creating Access Defined pathway Cut-off study Validation study Guidelines & Instruments ✓ Database lock for cut-off study ✓ Expected to be initiated in 1H ✓ Improved market access through and in-depth data analyses for 2026 following FDA feedback inclusion in K

  8. Slide 8: Continued NGAL growth in 2025 vs 2024 (Preliminary and unaudited)

    Continued NGAL growth in 2025 vs 2024 (Preliminary and unaudited) Revenue Q4 2025 vs Q4 2024, DKKm Revenue per quarter, DKKm FY 2025 vs 2024 US NGAL RUO +39% (+51%) Total revenue ROW NGAL +48% DKK 40.3m +11% (+13%) +47% ProNephro AKI (NGAL) +2.2m (+52%) 11.6 11.6 Total NGAL revenue +88% 10.6 10.4 (+

  9. Slide 9: NGAL Sales US continuing strong growth (Preliminary)

    NGAL Sales US continuing strong growth (Preliminary) US NGAL RUO sales (accumulated 12 months rolling at constant exchange rates) 20 19 +29% 17.8 18 17 16.1 16 15.1 15 14.2 13.7 14 13.0 DKKm 13 12.3 11.8 12 11 10.2 10.1 10 8.7 9 7.9 8 7 6 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 20

  10. Slide 10: Financial Guidance 2026

    Financial Guidance 2026 Total NGAL Revenue Total Revenue Adjusted EBITDA loss DKK 33-42m DKK 48-58m DKK 50-60m (20-50%) (20-45%) CONFIDENTIAL | © Copyright BioPorto | 10

  11. Slide 11: Q&A

    Q&A

BioPorto — FY2025 Earnings Presentation on 6ix